Nova Scotia NDP questions lack of pharmacare deal with Ottawa
HALIFAX - Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...
Government of Canada signs bilateral agreement with Nova Scotia to improve access to drugs for rare diseases
Today, the Honourable Kamal Khera, Canada's Minister of Health, and the Honourable Michelle Thompson, Nova Scotia's Minister of Health and Wellness, announced a bilateral agreement investing over $39 ...
BioPharma Dive3d
Arbor raises $74M amid genetic medicine’s funding slump
The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...
Hespress on MSN16d
How early detection could save lives in Primary Hyperoxaluria Type 1
Primary hyperoxaluria type 1 (PH1) is a metabolic stone disease that, if left undiagnosed, can have devastating consequences, including progressive kidney decline and end-stage kidney disease (ESKD).
C&EN18d
Correction to “Discovery of l-Lysine Dioxalate (LH1513) as a Novel Inhibitor of Calcium Oxalate Crystallization for Hyperoxaluria”
Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States The Cancer Institute of New Jersey, New ...
Pharmabiz23d
YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1
Primary Hyperoxaluria (PH) is a rare autosomal recessive genetic disorder caused by enzyme deficiencies in hepatic oxalate metabolism, leading to excessive oxalate production and systemic oxalate ...
Morningstar24d
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria (PH) is a rare autosomal recessive genetic disorder caused by enzyme deficiencies in hepatic oxalate metabolism, leading to excessive oxalate production and systemic oxalate ...
Yahoo Finance24d
Success for YolTech’s hyperoxaluria in vivo gene therapy in early-stage trial
The YOLT-203 in-vivo gene editing therapy was developed to treat patients living with primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine ...
Yahoo Finance24d
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
Tue, Feb 25, 2025, 3:15 AM 4 min read ...